Is Wall Street High Or Low On Pacific Biosciences of California Inc. (PACB)?

Pacific Biosciences of California Inc. (NASDAQ:PACB) finished Thursday with an addition of $1.69 to close at $25.56, an upside of 7.08 percent. An average of 2,552,080 shares of common stock have been traded in the last five days. There was a gain of $0.01 in the past week. The last 20 days have seen an average of 1,821,380 shares traded, while the 50-day average volume stands at 1,844,496.

PACB stock has decreased by -13.09% in the last month. The company shares reached their 1-month lowest point of $23.61 on 10/06/21. With the stock rallying to its 52-week high on 02/11/21, shares of the company touched a low of $11.22 and a high of $53.69 in 52 weeks. In spite of this, the price is down -52.39% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

9 days have passed since Pacific Biosciences of California Inc. (PACB) last reported insider trading activity. Kim Susan G., who is Chief Financial Officer, most recently acquired $20,272 shares at $25.75 per share on Sep 29. In this transaction, the insider spent $522,004. President & CEO, HENRY CHRISTIAN O, disposed of 90,520 shares at a price of $26.91 on Sep 16. The insider now owns more than $2,435,893 worth of shares. Prior to that, Director Ericson William W. went on to Sale 37,500 shares at $25.89 each on May 25. An amount of $971,058 was transacted.

Valuation Metrics

Pacific Biosciences of California Inc. (PACB) has a trailing price-to-earnings (P/E) ratio of 26.50 for the broader industry and 32.11 for the sector. This means investors are optimistic about the stock’s future prospects. In the last five years, Pacific Biosciences of California Inc.’s PE ratio has ranged between 568.33 and 288.22. The stock’s beta is 1.15. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 47.53, the price-to-book (PB) ratio at 19.66.

The quick ratio of Pacific Biosciences of California Inc. for the three months ended June 29 was 25.80, and the current ratio was 26.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 3.47 and a total debt to equity ratio of 0.00 For the recent quarter ending June 29. On the profitability front, the trailing 12-month gross margin is 42.70% against a 5-year average of 39.4%. Its gross profit as reported stood at $32.57 million compared to revenue of $78.89 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Pacific Biosciences of California Inc.’s return on assets was -9.60%, compared to -45.7% over the last five years. In the past year, the return on investment has been 8.20%, and the 5-year average is -60.3%. Meanwhile, the return on equity (ROE) for the past 12 months has been -30.80% and the 5-year average holds at -77.8%. For the broader industry, ROE averaged -2.89 over the past year.

Earnings Surprise

For the three-month period that ended June 29, Pacific Biosciences of California Inc. had $684.58 million in cash. The analyst consensus anticipated Pacific Biosciences of California Inc.’s latest quarter earnings to come in at -$0.21 per share, but it turned out to be -$0.21, a 0.00% surprise. For the recent quarter, EBITDA amounted to -$33.81 million. Shareholders own equity worth $199.0 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Pacific Biosciences of California Inc. (PACB) price momentum. RSI 9-day as of the close on 07 October was 45.85%, suggesting the stock is Neutral, with historical volatility in this time frame at 65.63%.

As of today, PACB’s price is $24.95 +0.04% or $0.01 from its 5-day moving average. PACB is currently trading -14.80% lower than its 20-day SMA and +9.28% higher than its 100-day SMA. However, the stock’s current price level is -18.88% below the SMA50 and +10.94% above the SMA200.

The stochastic %K and %D were 21.30% and 16.92%, respectively, and the average true range (ATR) was 1.56. With the 14-day stochastic at 39.00% and the average true range at 1.56, the RSI (14) stands at 43.93%. The stock has reached -0.28 on the 9-day MACD Oscillator while the 14-day reading was at -1.00.

Analyst Ratings

Canaccord Genuity launched coverage on Pacific Biosciences of California Inc. (NASDAQ: PACB) in its analyst report released on September 27, 2021. The firm assigned the stock a a Buy rating.The consensus rating for Pacific Biosciences of California Inc. (PACB) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell PACB, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 3 others rate it as a “buy”.

What is PACB’s price target for the next 12 months?

Analysts predict a range of price targets between $30.00 and $62.00, with a median target of $45.00. Taking a look at these predictions, the average price target given by analysts for Pacific Biosciences of California Inc. (PACB) stock is $45.60.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam